Original Article

You have full text access to this OnlineOpen article

Sequential interleukin 3 and granulocyte-macrophage–colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses

  1. Hillary H. Wu M.D.1,
  2. Moshe Talpaz M.D.1,
  3. Richard E. Champlin M.D.2,
  4. Susan R. Pilat R.N.1,
  5. Razelle Kurzrock M.D.1,†,*

Article first published online: 17 NOV 2003

DOI: 10.1002/cncr.11810

Issue

Cancer

Cancer

Volume 98, Issue 11, pages 2410–2419, 1 December 2003

Additional Information

How to Cite

Wu, H. H., Talpaz, M., Champlin, R. E., Pilat, S. R. and Kurzrock, R. (2003), Sequential interleukin 3 and granulocyte-macrophage–colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer, 98: 2410–2419. doi: 10.1002/cncr.11810

Author Information

  1. 1

    Department of Bioimmunotherapy, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Bone Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 745-2374

*Department of Bioimmunotherapy, Box 422, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030

Publication History

  1. Issue published online: 17 NOV 2003
  2. Article first published online: 17 NOV 2003
  3. Manuscript Accepted: 28 AUG 2003
  4. Manuscript Received: 20 AUG 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (138K)

REFERENCES

  • 1
    Stewart FM. Hypoplastic/aplastic anemia. Role of bone marrow transplantation. Med Clin North Am. 1992; 76: 683–697.
  • 2
    Storb R, Longton G, Anasetti C, et al. Changing trends in marrow transplantation for aplastic anemia. Bone Marrow Transplant. 1992; 10 (Suppl 1): 45–52.
  • 3
    Hong R. Bone marrow transplantation. Adv Pediatr. 1993; 40: 101–124.
  • 4
    Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995; 85: 3367–3377.
  • 5
    Tsai TW, Freytes CO. Allogenic bone marrow transplantation for leukemias and aplastic anemia. Adv Intern Med. 1997; 42: 423–451.
  • 6
    Ball SE. The modern management of severe aplastic anaemia. Br J Haematol. 2000; 110: 41–53.
    Direct Link:
  • 7
    Camitta B, O'Reilly RJ, Sensenbrenner L, et al. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood. 1983; 62: 883–888.
  • 8
    Young N, Griffith P, Brittain E, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood. 1988; 72: 1861–1869.
  • 9
    Noel P, Solberg LA. Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment. Crit Rev Oncol Hematol. 1992; 12: 193–215.
  • 10
    Cazzola M. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. Int J Hematol. 2000; 72: 134–138.
  • 11
    Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993; 82: 677–681.
  • 12
    Anderson JE. Bone marrow transplantation for myelodysplasia. Blood Rev. 2000; 14: 63–77.
  • 13
    de Witte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Bone Marrow Transplant. 1989; 4 (Suppl 3): 38–39.
  • 14
    O'Donnell MR, Nademanee AP, Snyder DS, et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol. 1987; 5: 1822–1826.
  • 15
    Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994; 12: 2527–2534.
  • 16
    de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000; 110: 620–630.
    Direct Link:
  • 17
    Armitage JO, Dick FR, Needleman SW, et al. Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rev. 1981; 65: 601–605.
  • 18
    Preisler HD, Raza A, Barcos M, et al. High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study. Am J Hematol. 1986; 23: 131–134.
    Direct Link:
  • 19
    Mertelsmann R, Tzvi Thaler H, To L, et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood. 1980; 56: 773–781.
  • 20
    Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol. 1986; 63: 477–483.
    Direct Link:
  • 21
    Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996; 88: 2473–2479.
  • 22
    Steinmetz HT, Schulz A, Staib P, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol. 1999; 78: 418–425.
  • 23
    Champlin RE, Nimer SD, Ireland P, et al. Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor. Blood. 1989; 73: 694–699.
  • 24
    Guinan EC, Sieff CA, Oette DH, et al. A Phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia. Blood. 1990; 76: 1077–1082.
  • 25
    Grosfeld JL, Du X, Williams DA. Interleukin-11: its biology and prospects for clinical use. Jpn J Parent Enter Nutr. 1999; 23: S67–S69.
  • 26
    Seipelt G, Ottmann OG, Hoelzer D. Cytokine therapy for myelodysplastic syndrome. Curr Opin Hematol. 2000; 7: 156–160.
  • 27
    Kurzrock R, Cortes J, Thomas DA, et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001; 19: 4165–4172.
  • 28
    Kurzrock R. Hematopoietic growth factors. In: BastR, KufeD, PollockR, et al., editors. Cancer medicine, 5th ed. New York: Decker Inc., 2000: 835–859.
  • 29
    Kurzrock R, Gratwohl A, Paquette RL, et al. Trilineage responses seen with stem cell factor (stemgen, SCF) and filgrastim (G-CSF) treatment in aplastic anemia (AA) patients (pts) [abstract]. Br J Haematol. 1998; 102: 2.
  • 30
    Ganser A, Lindemann A, Seipelt G, et al. Effects of recombinant human interleukin-3 in aplastic anemia. Blood. 1990; 76: 1287–1292.
  • 31
    Kurzrock R, Talpaz M, Estrov Z, et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol. 1991; 9: 1241–1250.
  • 32
    Estrov Z, Kurzrock R, Talpaz M, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Ann Hematol. 1991; 63: 297–301.
  • 33
    Farese AM, Williams DE, Seiler FR, et al. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood. 1993; 82: 3012–3018.
  • 34
    Karnofsky DA AW, Craver LF, Burchenal JH. Use of nitrogen mustard in palliative treatment of carcinoma; with particular reference to bronchogenic carcinoma. Cancer. 1948; 1: 634–656.
    Direct Link:
  • 35
    Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000; 132: 364–368.
  • 36
    Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000; 18: 2852–2861.
  • 37
    Nash RA, Kurzrock R, DiPersio J, et al. A Phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000; 6: 25–34.
  • 38
    Kurzrock R, Talpaz M, Gutterman JU. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am J Med. 1992; 93: 41–48.
  • 39
    Lindemann A, Mertelsmann R. Interleukin-3 and its receptor. Cancer Treat Res. 1995; 80: 107–142.
  • 40
    Eder M, Geissler G, Ganser A. IL-3 in the clinic. Stem Cells. 1997; 15: 327–333.
    Direct Link:
  • 41
    Metcalf D, Begley CG, Johnson GR, et al. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood. 1986; 68: 46–57.
  • 42
    Kawano TY, Hirao A, Watanabe T, et al. Production of interleukin 3 and granulocyte-macrophage colony-stimulating factor from stimulated blood mononuclear cells in patients with aplastic anemia. Exp Hematol. 1992; 20: 1125–1128.
  • 43
    Dunbar CE, Smith DA, Kimball J, et al. Treatment of Diamond–Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: sustained remissions following IL-3. Br J Haematol. 1991; 79: 316–321.
    Direct Link:
  • 44
    Bastion Y, Campos L, Roubi N, et al. IL-3 increases marrow and peripheral erythroid precursors in chronic pure red cell aplasia presenting in childhood. Br J Haematol. 1995; 89: 413–416.
    Direct Link:
  • 45
    Nemunaitis J, Appelbaum FR, Singer JW, et al. Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood. 1993; 82: 3273–3278.
  • 46
    Emerson SG, Yang YC, Clark SC, et al. Human recombinant granulocyte-macrophage colony stimulating factor and interleukin 3 have overlapping but distinct hematopoietic activities. J Clin Invest. 1988; 82: 1282–1287.
  • 47
    Naeim F, Champlin R, Nimer S. Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF. Hematol Pathol. 1990; 4: 79–85.
  • 48
    Estey EH, Kurzrock R, Talpaz M, et al. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol. 1991; 77: 291–295.
    Direct Link:
  • 49
    Gibson FM, Scopes J, Daly S, et al. In vitro response of normal and aplastic anemia bone marrow to mast cell growth factor and in combination with granulocyte-macrophage colony-stimulating factor and interleukin-3. Exp Hematol. 1994; 22: 302–312.
  • 50
    Herrmann F, Lindemann A, Raghavachar A, et al. In vivo recruitment of GM-CSF-response myelopoietic progenitor cells by interleukin-3 in aplastic anemia. Leukemia. 1990; 4: 671–672.
  • 51
    Haas R, Ehrhardt R, Witt B, et al. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma. Bone Marrow Transplant. 1993; 12: 643–649.
  • 52
    Fay JW, Lazarus H, Herzig R, et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a Phase I/II multicenter study. Blood. 1994; 84: 2151–2157.
  • 53
    O'Shaughnessy JA, Venzon DJ, Gossard M, et al. A Phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood. 1995; 86: 2913–2921.
  • 54
    Fay J, Fogerson R, Schoendorfer D, et al. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma. Clin Chem. 1996; 42: 34–38.
  • 55
    Vose JM, Pandite AN, Beveridge RA, et al. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial. J Clin Oncol. 1997; 15: 1617–1623.
  • 56
    Nand S, Sosman J, Godwin JE, et al. A Phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood. 1994; 83: 357–360.
View Full Article (HTML) Get PDF (138K)